GLP-1 Medications in Children Linked to Nutritional Deficiencies, Study Warns

Rising Concern Over Vitamin D and Nutrient Gaps

Children and adolescents taking GLP-1 medications for weight loss, prediabetes, or type 2 diabetes face a significant nutritional risk that has largely gone unmonitored. Research published in Childhood Obesity examined 2,031 young patients ages 10 to 17 and found that nearly one in six (16.8%) developed a nutritional deficiency within their first year of treatment. Vitamin D deficiency emerged as the most prevalent issue, diagnosed in 12.4% of children shortly after starting these medications. The finding raises alarm among pediatric researchers who emphasize that adolescence represents a critical window for bone development, physical growth, and overall biological maturation—making nutrient deficiencies potentially more consequential in younger patients than in adults.

Why GLP-1 Medications Create Nutritional Challenges

GLP-1 drugs work by reducing appetite and suppressing food intake, which helps patients lose weight and manage blood sugar. However, this same mechanism that makes the medications effective for weight management can inadvertently create nutritional gaps. Researchers at Ann & Robert H. Lurie Children's Hospital of Chicago stressed that vitamin D, iron, and calcium warrant particular vigilance during childhood and adolescence, since deficiencies in these nutrients during growth years can have lasting consequences for skeletal integrity and developmental trajectories. The period of rapid growth and pubertal changes demands heightened nutritional support—yet GLP-1 medications can compromise the very appetite signals that naturally drive adequate food consumption.

The analysis examined national administrative claims data spanning 2017 through 2022, pulled from a database covering more than 100 million patients. Among the 2,031 young GLP-1 users identified, liraglutide (marketed as Victoza for diabetes and Saxenda for weight loss) dominated prescribing patterns at 78.6% of all GLP-1 medications. Dulaglutide (Trulicity) accounted for 10.4% of prescriptions, while semaglutide (Ozempic and Wegovy) represented 9.1%.

The Critical Gap in Nutritional Oversight

Perhaps most troubling is the apparent absence of proactive nutritional management in clinical practice. The researchers discovered that only 5% of patients received any form of nutritional counseling within the first 30 days after starting GLP-1 treatment. Even extending the window to six months, fewer than 25% of young patients received nutritional guidance. This lag means that by the time many children develop detectable deficiencies, months may have passed without intervention—a particularly concerning timeline during adolescence when developmental windows are narrow and bone health trajectories are being established.

Shifting Toward Prevention Rather Than Detection

Research leaders are now advocating for a fundamental shift in how pediatricians approach GLP-1 prescribing. Rather than monitoring children for deficiencies after they develop, the recommendation centers on initiating nutritional counseling and support simultaneously with GLP-1 therapy initiation. This proactive stance acknowledges that appetite suppression creates predictable nutritional risks, and those risks deserve prevention strategies implemented from day one of treatment. The researchers emphasize that with knowledge of these risks now established, clinicians are positioned to protect children during a critical developmental period by ensuring adequate intake of essential micronutrients before deficiencies can cause lasting harm.